Cresset, a provider of software and contract research services for small molecule discovery and design, has signed a three-way strategic agreement to speed up drug design.
Cressit
The company’s commercial director, Dr David Bardsley, visited the School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, China, to sign an agreement for the drug design technology that has been developed within the Research Centre for Drug Discovery (RCDD). Initiated by an invitation from Professor Jun Xu, RCDD, the visit was hosted by the dean of the school, Wenhao Hu, and the vice dean of the School for International Development, Huichang Bi.
A further agreement was signed by Bardsley and the chairman of iPrecision Medicine Technology, DeKang Zhang, that will see Cresset promote iPrecision software and technology globally.
Bardsley commented, “This British-Chinese three-way agreement brings together expertise and innovation in development of technologies for computational molecule design. I look forward to working with each organisation to establish global distribution channels.”